Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by phenylbutyrate on L1210 leukemic cells

Leukemia and Lymphoma

Volumn 45, Issue 1, 2004, Pages 147-154

  Lemaire, Maryse ^a   Momparler, Louise F ^a   Farinha, Nuno Jorge ^b   Bernstein, Mark ^b   Momparler, Richard L ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

5 aza 2 deoxycytidine; Chemotherapy; DNA methylation; Histone acetylation; leukemia; Phenylbutyrate

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CHROMATIN STRUCTURE; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DNA SYNTHESIS; DRUG POTENTIATION; GENE ACTIVATION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA; DNA REPLICATION; DRUG SYNERGISM; GENES, TUMOR SUPPRESSOR; HL-60 CELLS; HUMANS; LEUKEMIA; MALE; MICE; PHENYLBUTYRATES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 0842322916     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000149304     Document Type: Article

References (32)

1. Linker, C.A., Levitt, L.J., O'Donnell, M., Forman, S.J. and Ries, C.A. (1991) "Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report", Blood, 78, 2814-2822.
2. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., et al. (1994) "Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B", The New Englan Journal of Medicine, 331, 896-903.
3. Jones, P.A. and Laird, P.W. (1999) "Cancer epigenetics comes of age", Nature Genetics, 21, 163-167.
4. Jones, P.A. and Baylin, S. (2002) "The fundamental role of epigenetic events in cancer", Nature Reviews. Genetics, 3, 415-428.
5. Strahl, B.D. and Allis, C.D. (2000) "The language of covalent histone modifications". Nature, 403, 41-45.
6. Momparler, R.L. and Bovenzi, V. (2000) "DNA methylation and Cancer", Journal of Cellular Physiology, 183, 145-154.
7. Jones, P.L., Jan Veenstra, G.C., Wade, P.A., Vennaak, D., Kass, S.U., Landsberger, N., et al. (1998) "Methylated DNA and MeCP2 recruit histone deacetylases to repress transcription", Nature Genetics, 19, 187-191.
8. Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N., et al. (1998) "Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex", Nature, 393, 386-389.
9. Pinto, A., Attadia, V., Fusco, A., Ferrara, F., Spada, O.A., and Di Fiore, P.P. (1984) "5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias", Blood, 64, 922-929.
10. Momparler, R.L., Dore, B.T. and Momparler, L.F. (1990) "Effect of 5-aza-2′-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells", Cancer Letters, 54, 21-28.
11. Wilson, V.L., Jones, P.A. and Momparler, R.L. (1983) "Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action", Cancer Research, 43, 3493-3496.
12. Vigushin, D.M. and Coombes, R.C. (2002) "Histone deacetylase inhibitors in cancer treatment", Anticancer Drugs, 13, 1-13. Review.
13. Marks, P.A., Richon, V.M. and Rifkind, R.A. (2000) "Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells", Journal of the National Cancer Institute, 92, 1210-1216.
14. Gore, S.D. and Carducci, M.A. (2000) "Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylases inhibitors", Expert Opinion on Investigational Drugs, 9, 2923-2934.
15. Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M.P., Herman, J.G., et al. (2002) "A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer", Nature Genetics, 31, 141-149.
16. Cameron, E.E., Bachman, K.E., Myöhänen, B.S., Herman, J.G. and Baylin, S.B. (1999) "Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer", Nature Genetics, 21, 103-107.
17. Bovenzi, V. and Momparler, R.L. (2001) "Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells", Cancer Chemotherapy and Pharmacology, 48, 71-76.
18. Primeau, M., Gagnon, J. and Momparler, R.L. (2003) "Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells", International Journal of Cancer, 103, 177-184.
19. Gagnon, J., Shaker, S., Primeau, M., Hurtubise, A. and Momparler, R.L. (2003) "Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of sigma 14-3-3, E-cadherin, and Timp3 expression in human breast carcinoma cells". Anti-cancer Drugs, 13, 193-202.
20. Boivin, A.J., Momparler, L.F., Hurtubise, A. and Momparler, R.L. (2002) "Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells", Anticancer Drugs, 13, 869-874.
21. Weiser, T.S., Guo, Z.S., Ohnmacht, G.A., Parkhurst, M.L., Tong-On, P., Marincola, F.M., et al. (2001) "Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1", Journal of Immunotherapy, 24, 151-161.
22. Momparler, R.L. and Gonzales, F.A. (1978) "Effect of Intravenous Infusion of 5-Aza-2′-Deoxycytidine on Survival Time of Mice with L1210 Leukemia", Cancer Research, 38, 2673-2678.
23. Momparler, R.L., Rivard, G.E. and Gyger, M. (1985) "Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia", Pharmacology & Therapeutics, 30, 277-286.
24. Momparler, R.L., Bouchard, J., Onetto, N. and Rivard, G.E. (1984) "5-Aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation", Leukemia Research, 8, 181-185.
25. Rivard, G.E., Momparler, R.L., Demers, J., Benoit, P., Raymond, R., Lin, K.T., et al. (1981) "Phase I study on 5-AZA-2′-deoxycytidine in children with acute leukemia", Leukemia Research, 5, 453-462.
26. Gore, S.D., Weng, L.J., Figg, W.D., Zhai, S., Donehower, R.C., Dover, G., et al. (2002) "Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia", Clinical Cancer Research, 8, 963-970.
27. He, L.Z., Tolentino, T., Grayson, P., Zhong, S., Warrel, R.P., Rifkind, R.A., et al. (2001) "Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia", The Journal of Clinical Investigation, 108, 1321-1330.
28. Warrel, R.P., He, L.Z., Richon, V., Calleja, E. and Pandolfi, P.P. (1998) "Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase", Journal of the National Cancer Institute, 90, 1621-1625.
29. Momparler, R.L. (1980) "In vitro systems for the evaluation of combination chemotherapy", Pharmacology & Therapeutics, 8, 21-25.
30. Valeriote, F. and Lin, H. (1975) "Synergistic interaction of anticancer drugs: a cellular perspective", Cancer Chemotherapy Reports, 59, 895-899.
31. Toyota, M., Kopecky, K.J., Toyota, M.O., Jair, K.W., Willman, C.L. and Issa, J.P. (1997) "Methylation profiling in acute myeloid leukemia", Neoplasia, 97, 2823-2829.
32. Johnstone, R.W. (2002) "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer", Nature Reviews. Drug Discovery, 1, 287-299.